Cyndeo Wealth Partners LLC Buys 154 Shares of Danaher Co. (NYSE:DHR)

Cyndeo Wealth Partners LLC boosted its holdings in shares of Danaher Co. (NYSE:DHR) by 1.8% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 8,579 shares of the conglomerate’s stock after acquiring an additional 154 shares during the quarter. Cyndeo Wealth Partners LLC’s holdings in Danaher were worth $1,969,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in DHR. Decker Retirement Planning Inc. acquired a new position in shares of Danaher in the 4th quarter worth approximately $31,000. Teachers Insurance & Annuity Association of America acquired a new position in shares of Danaher in the 3rd quarter worth approximately $39,000. MidAtlantic Capital Management Inc. acquired a new position in shares of Danaher in the 3rd quarter worth approximately $40,000. FSA Wealth Management LLC acquired a new position in shares of Danaher during the 3rd quarter valued at $50,000. Finally, Darwin Wealth Management LLC acquired a new position in shares of Danaher during the 3rd quarter valued at $55,000. 79.05% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

DHR has been the topic of a number of research reports. Citigroup dropped their target price on shares of Danaher from $305.00 to $285.00 and set a “buy” rating on the stock in a research report on Monday, January 6th. Robert W. Baird dropped their target price on shares of Danaher from $278.00 to $277.00 and set an “outperform” rating on the stock in a research report on Wednesday, October 23rd. KeyCorp boosted their target price on shares of Danaher from $290.00 to $310.00 and gave the company an “overweight” rating in a research report on Wednesday, October 23rd. Wolfe Research upgraded shares of Danaher from a “peer perform” rating to an “outperform” rating and set a $285.00 target price on the stock in a research report on Thursday, October 31st. Finally, Barclays decreased their price target on shares of Danaher from $285.00 to $275.00 and set an “equal weight” rating for the company in a research note on Wednesday, October 23rd. Six equities research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $285.55.

Danaher Stock Performance

NYSE DHR opened at $245.95 on Friday. Danaher Co. has a 1 year low of $225.42 and a 1 year high of $281.70. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.37 and a quick ratio of 1.01. The firm has a market cap of $177.65 billion, a price-to-earnings ratio of 46.94, a PEG ratio of 4.43 and a beta of 0.83. The company has a fifty day moving average price of $235.33 and a 200-day moving average price of $253.45.

Danaher Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Friday, December 27th will be given a dividend of $0.27 per share. The ex-dividend date of this dividend is Friday, December 27th. This represents a $1.08 annualized dividend and a yield of 0.44%. Danaher’s payout ratio is currently 20.61%.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.